PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
Provided By GlobeNewswire
Last update: Mar 27, 2025
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
Conference call and webcast today at 8:00 a.m. Eastern Time
Read more at globenewswire.comNASDAQ:PDSB (10/14/2025, 1:52:26 PM)
0.9306
-0.03 (-3.06%)
Find more stocks in the Stock Screener
